Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2011

Open Access 01-12-2011 | Research

Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer

Authors: Fabrizio Consorti, Gianluca Di Tanna, Francesca Milazzo, Alfredo Antonaci

Published in: World Journal of Surgical Oncology | Issue 1/2011

Login to get access

Abstract

Background

Many studies have reported an increased risk of developing a second primary malignancy (SPM) of the breast in women treated for thyroid cancer. In this study, we investigated several potential risk factors for this association. The aim of this retrospective cohort study was to identify a subgroup of women surgically treated for papillary thyroid cancer that may benefit from more careful breast cancer screening.

Methods

A total of 101 women surgically treated for papillary thyroid cancer from 1996 to 2009 with subsequent follow-up were interviewed by phone regarding personal risk factors and lifestyle habits. Only 75 questionnaires could be evaluated due to a 25.7% rate of patients not retrieved or refusing the interview. Data analysis was performed using a multivariate logistic model.

Results

The standardised incidence ratio (SIR) for breast cancer was 3.58 (95% IC 1.14 - 8.37). Our data suggest a protective effect of multiparity on the development of a SPM of the breast (O.R. 0.15; 95% IC 0.25 - 0.86). Significant associations were not found with other known risk factors including Body Mass Index (BMI), age at first tumour, concurrent metabolic diseases, smoking, physical activity and familiarity.

Conclusions

This study confirms that a higher incidence of SPM of the breast is observed in women treated for papillary thyroid cancer. Additionally, this risk is increased by nulliparity, thus a strict breast screening program for nulliparous women treated for thyroid cancer may be advisable.
Appendix
Available only for authorised users
Literature
2.
go back to reference Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, Straus S, Brierley JD, Tsang RW, Gafni A, Rotstein L, Sawka AM: Second Primary Malignancy Risk in Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis. THYROID. 2007, 17: 1277-1289. 10.1089/thy.2007.0171.CrossRefPubMed Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, Straus S, Brierley JD, Tsang RW, Gafni A, Rotstein L, Sawka AM: Second Primary Malignancy Risk in Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis. THYROID. 2007, 17: 1277-1289. 10.1089/thy.2007.0171.CrossRefPubMed
3.
go back to reference Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin R: The Development of Breast Carcinoma in Women with Thyroid Carcinoma. CANCER. 2001, 92: 225-231. 10.1002/1097-0142(20010715)92:2<225::AID-CNCR1313>3.0.CO;2-B.CrossRefPubMed Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin R: The Development of Breast Carcinoma in Women with Thyroid Carcinoma. CANCER. 2001, 92: 225-231. 10.1002/1097-0142(20010715)92:2<225::AID-CNCR1313>3.0.CO;2-B.CrossRefPubMed
4.
go back to reference Adjadj E, Rubino C, Shamsaldim A, G Lê M, Schlumberger M, de Vathaire F: The Risk of Multiple Primary Breast and Thyroid Carcinomas. CANCER. 2003, 6: 1309-1317.CrossRef Adjadj E, Rubino C, Shamsaldim A, G Lê M, Schlumberger M, de Vathaire F: The Risk of Multiple Primary Breast and Thyroid Carcinomas. CANCER. 2003, 6: 1309-1317.CrossRef
5.
go back to reference Canchola AJ, Horn-Ross PL, Purdie DM: Risk of Second Primary Malignancies in Women with Papillary Thyroid Cancer. Am J Epidemiol. 2006, 163: 521-527. 10.1093/aje/kwj072.CrossRefPubMed Canchola AJ, Horn-Ross PL, Purdie DM: Risk of Second Primary Malignancies in Women with Papillary Thyroid Cancer. Am J Epidemiol. 2006, 163: 521-527. 10.1093/aje/kwj072.CrossRefPubMed
6.
go back to reference Morris JA, Gardner MJ: Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed). 1988, 296 (6632): 1313-1316. 10.1136/bmj.296.6632.1313.CrossRef Morris JA, Gardner MJ: Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed). 1988, 296 (6632): 1313-1316. 10.1136/bmj.296.6632.1313.CrossRef
7.
go back to reference Piscitelli P, Santoriello A, Buonaguro FM, Di Maio M, Iolascon G, Gimigliano F, Marinelli A, Distante A, Serravezza G, Sordi E, Cagossi K, Artioli F, Santangelo M, Fucito A, Gimigliano R, Brandi ML, Crespi M, Giordano A: Incidence Of Breast Cancer In Italy: Mastectomies And Quadrantectomies Performed Between 2000 and 2005. J Exp & Clin Cancer Res. 2009, 28: 86-10.1186/1756-9966-28-86.CrossRef Piscitelli P, Santoriello A, Buonaguro FM, Di Maio M, Iolascon G, Gimigliano F, Marinelli A, Distante A, Serravezza G, Sordi E, Cagossi K, Artioli F, Santangelo M, Fucito A, Gimigliano R, Brandi ML, Crespi M, Giordano A: Incidence Of Breast Cancer In Italy: Mastectomies And Quadrantectomies Performed Between 2000 and 2005. J Exp & Clin Cancer Res. 2009, 28: 86-10.1186/1756-9966-28-86.CrossRef
8.
go back to reference Dal Maso L, Lise M, Zambon P, Falcini F, Crocetti E, Serraino D, Cirilli C, Zanetti R, Vercelli M, Ferretti S, Stracci F, De Lisi V, Busco S, Tagliabue G, Budroni M, Tumino R, Giacomin A & Franceschi S for AIRTUM Working Group: Incidence Of Thyroid Cancer In Italy, 1991-2005: Time Trends And Age-Period-Cohort Effects. Ann Oncol. 2010, Dal Maso L, Lise M, Zambon P, Falcini F, Crocetti E, Serraino D, Cirilli C, Zanetti R, Vercelli M, Ferretti S, Stracci F, De Lisi V, Busco S, Tagliabue G, Budroni M, Tumino R, Giacomin A & Franceschi S for AIRTUM Working Group: Incidence Of Thyroid Cancer In Italy, 1991-2005: Time Trends And Age-Period-Cohort Effects. Ann Oncol. 2010,
9.
go back to reference La Vecchia C, Bosetti C, Bertuccio P, Negri E, Boyle P, Levi F: Cancer Mortality In Europe, 2000-2004, And An Overview Of Trends Since 1975. Ann Oncol. 2010, 21 (6): 1323-1360. 10.1093/annonc/mdp530.CrossRefPubMed La Vecchia C, Bosetti C, Bertuccio P, Negri E, Boyle P, Levi F: Cancer Mortality In Europe, 2000-2004, And An Overview Of Trends Since 1975. Ann Oncol. 2010, 21 (6): 1323-1360. 10.1093/annonc/mdp530.CrossRefPubMed
11.
go back to reference Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD: The Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2008, 93 (2): 504-515. 10.1210/jc.2007-1154.CrossRefPubMed Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD: The Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2008, 93 (2): 504-515. 10.1210/jc.2007-1154.CrossRefPubMed
12.
go back to reference Lester SC, Cotran RS: Mammary Gland. Robbins Pathologic Basis Of Disease. Edited by: Cotran, Kumar, Collins. 1999, Philadelphia: Saunders, 1282-1284. 6 Lester SC, Cotran RS: Mammary Gland. Robbins Pathologic Basis Of Disease. Edited by: Cotran, Kumar, Collins. 1999, Philadelphia: Saunders, 1282-1284. 6
13.
go back to reference Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M: Second Primary Malignancies In Thyroid Cancer Patients. Br J of Cancer. 2003, 89: 1638-1644. 10.1038/sj.bjc.6601319.CrossRef Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M: Second Primary Malignancies In Thyroid Cancer Patients. Br J of Cancer. 2003, 89: 1638-1644. 10.1038/sj.bjc.6601319.CrossRef
14.
go back to reference Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP: Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis. THYROID. 2009, 19: 451-456. 10.1089/thy.2008.0392.CrossRefPubMed Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP: Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis. THYROID. 2009, 19: 451-456. 10.1089/thy.2008.0392.CrossRefPubMed
15.
go back to reference Paes JE, Hua K, Nagy R, Kloos RT, Jarjoura D, and Ringel MD: The Relationship Between Body Mass Index And Thyroid Cancer Pathology Features And Outcomes: A Clinicopathological Cohort Study. J Clin Endocrinol Metab. 2010, 95 (9): 4244-4250. 10.1210/jc.2010-0440.PubMedCentralCrossRefPubMed Paes JE, Hua K, Nagy R, Kloos RT, Jarjoura D, and Ringel MD: The Relationship Between Body Mass Index And Thyroid Cancer Pathology Features And Outcomes: A Clinicopathological Cohort Study. J Clin Endocrinol Metab. 2010, 95 (9): 4244-4250. 10.1210/jc.2010-0440.PubMedCentralCrossRefPubMed
16.
go back to reference Hall LC, Salazar EP, Kanea SR, Liu N: Effects Of Thyroid Hormones On Human Breast Cancer Cell Proliferation. J Steroid Biochem & Molec Biol. 2008, 109: 57-66. 10.1016/j.jsbmb.2007.12.008.CrossRef Hall LC, Salazar EP, Kanea SR, Liu N: Effects Of Thyroid Hormones On Human Breast Cancer Cell Proliferation. J Steroid Biochem & Molec Biol. 2008, 109: 57-66. 10.1016/j.jsbmb.2007.12.008.CrossRef
Metadata
Title
Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer
Authors
Fabrizio Consorti
Gianluca Di Tanna
Francesca Milazzo
Alfredo Antonaci
Publication date
01-12-2011
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2011
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-9-88

Other articles of this Issue 1/2011

World Journal of Surgical Oncology 1/2011 Go to the issue